- Home
- BTAI vs NEUP Comparison
BTAI vs NEUP Comparison
Compare BTAI & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- NEUP
- Stock Information
- Founded
- BTAI 2017
- NEUP 1996
- Country
- BTAI United States
- NEUP United States
- Employees
- BTAI N/A
- NEUP N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- BTAI Health Care
- NEUP
- Exchange
- BTAI Nasdaq
- NEUP Nasdaq
- Market Cap
- BTAI 10.7M
- NEUP 9.3M
- IPO Year
- BTAI 2018
- NEUP N/A
- Fundamental
- Price
- BTAI $1.46
- NEUP $4.74
- Analyst Decision
- BTAI Buy
- NEUP Strong Buy
- Analyst Count
- BTAI 5
- NEUP 1
- Target Price
- BTAI $42.60
- NEUP $21.00
- AVG Volume (30 Days)
- BTAI 97.3K
- NEUP 10.9K
- Earning Date
- BTAI 05-12-2025
- NEUP 05-23-2025
- Dividend Yield
- BTAI N/A
- NEUP N/A
- EPS Growth
- BTAI N/A
- NEUP N/A
- EPS
- BTAI N/A
- NEUP N/A
- Revenue
- BTAI $1,852,000.00
- NEUP $662,715.00
- Revenue This Year
- BTAI $41.00
- NEUP N/A
- Revenue Next Year
- BTAI $197.21
- NEUP N/A
- P/E Ratio
- BTAI N/A
- NEUP N/A
- Revenue Growth
- BTAI 5.47
- NEUP N/A
- 52 Week Low
- BTAI $1.29
- NEUP $2.12
- 52 Week High
- BTAI $42.08
- NEUP $15.24
- Technical
- Relative Strength Index (RSI)
- BTAI 37.90
- NEUP N/A
- Support Level
- BTAI $1.34
- NEUP N/A
- Resistance Level
- BTAI $1.64
- NEUP N/A
- Average True Range (ATR)
- BTAI 0.15
- NEUP 0.00
- MACD
- BTAI -0.01
- NEUP 0.00
- Stochastic Oscillator
- BTAI 16.56
- NEUP 0.00
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.